ProShare Advisors
ADMS

ProShare Advisors’s Adamas Pharmaceuticals ADMS Stock Holding History

ProShare Advisors’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-10,090
Closed -$52K – 1815
2019
Q3 		$52K Sell
10,090
-302
-3% -$1.86K ﹤0.01% 1598
2019
Q2 		$64K Sell
10,392
-1,312
-11% -$7.55K ﹤0.01% 1563
2019
Q1 		$83K Buy
11,704
+93
+0.8% +$836 ﹤0.01% 1585
2018
Q4 		$99K Sell
11,611
-2,166
-16% -$28.2K ﹤0.01% 1474
2018
Q3 		$276K Sell
13,777
-458
-3% -$10.8K ﹤0.01% 1407
2018
Q2 		$368K Sell
14,235
-356
-2% -$9.86K ﹤0.01% 1266
2018
Q1 		$349K Buy
14,591
+101
+0.7% +$3.18K ﹤0.01% 1254
2017
Q4 		$491K Buy
14,490
+801
+6% +$22.4K ﹤0.01% 1140
2017
Q3 		$290K Buy
13,689
+918
+7% +$16.8K ﹤0.01% 1150
2017
Q2 		$223K Sell
12,771
-1,010
-7% -$16.7K ﹤0.01% 1295
2017
Q1 		$241K Sell
13,781
-3,424
-20% -$58.3K ﹤0.01% 1358
2016
Q4 		$291K Buy
17,205
+1,739
+11% +$26.9K ﹤0.01% 1384
2016
Q3 		$254K Sell
15,466
-2,672
-15% -$40.6K ﹤0.01% 1217
2016
Q2 		$275K Buy
18,138
+794
+5% +$13.1K ﹤0.01% 1246
2016
Q1 		$251K Buy
17,344
+1,017
+6% +$17.1K ﹤0.01% 1292
2015
Q4 		$462K Buy
+16,327
New +$275K 0.01% 1067

Other funds holding ADMS

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

ProShare Advisors's ADMS Position: Q4 2019 in Review

ProShare Advisors sold out of Adamas Pharmaceuticals (ADMS) in Q4 2019, closing a stake of 10,090 shares — an estimated $52K sold.

ProShare Advisors first reported a position in ADMS in Q4 2015 and held it in 16 quarters. The position peaked at $491K in Q4 2017. 79 funds tracked by Wall St. Rank hold ADMS as of Q4 2019.

  • ProShare Advisors reported no remaining Adamas Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • ProShare Advisors sold 10,090 Adamas Pharmaceuticals shares in Q4 2019, an estimated $52K.
  • ProShare Advisors first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 16 quarters.
  • ProShare Advisors's Adamas Pharmaceuticals position peaked at $491K in Q4 2017.
  • 79 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2019.

Based on ProShare Advisors's 13F filing for Q4 2019, filed 12 Feb 2020.